Meta-Analysis
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 21, 2019; 25(27): 3649-3663
Published online Jul 21, 2019. doi: 10.3748/wjg.v25.i27.3649
Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis
Jing Cao, Fan-Hua Kong, Xi Liu, Xiao-Bo Wang
Jing Cao, Xiao-Bo Wang, Department of Surgery, Technical University of Munich, Munich 80333, Germany
Fan-Hua Kong, Xi Liu, Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
Author contributions: Cao J performed the research; Cao J, Kong FH and Liu X analyzed the data; Cao J drafted the paper; Wang XB designed the research and revised the article.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
PRISMA 2009 Checklist statement: The manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Xiao-Bo Wang, MD, Surgeon, Department of Surgery, Technical University of Munich, Arcisstrasse 21, Munich 80333, Germany. xiaobo.wang@tum.de
Telephone: +49-152-37359648
Received: March 18, 2019
Peer-review started: March 18, 2019
First decision: April 11, 2019
Revised: April 18, 2019
Accepted: June 7, 2019
Article in press: June 8, 2019
Published online: July 21, 2019
Processing time: 123 Days and 12.3 Hours
Core Tip

Core tip: Hepatocellular carcinoma has been revealed as the second most common cause of cancer-related deaths worldwide. Though several analyses have supported the effective benefit of cellular immunotherapy when combined with specific hepatocellular carcinoma treatment, the efficacy and necessity of cellular immunotherapy after different interventional therapy remains to be interrogated. Our study suggested that the combination of immunotherapy with dendritic cells, cytokine-induced killer cells and a combination of the two with various routine hepatocellular carcinoma treatments could evidently improve patients’ prognosis by increasing the overall survival and reduce the recurrence of the malignancy.